A novel cell-based assay for the evaluation of anti-ras compounds
1993

A New Test for Anti-Ras Drugs

publication Evidence: moderate

Author Information

Author(s): D.C. Jenkins, J.N. Stables, J. Wilkinson, P. Topley, L.S. Holmes, D.J. Linstead, E.B. Rapson

Primary Institution: Department of Cell Biology, Wellcome Research Laboratories

Hypothesis

Can drugs that affect ras oncogenes lead to the detransformation of tumors?

Conclusion

The study found that certain compounds can selectively inhibit the growth of cells with mutated ras oncogenes.

Supporting Evidence

  • Compounds like fumagillin showed strong effects against cells with mutated ras.
  • 8-bromo cAMP caused morphological changes in transformed cells.
  • Microinjection of an anti-ras antibody led to a reversion of the transformed phenotype.

Takeaway

Researchers created a test to see if drugs can help fight cancer by targeting a specific gene that can cause tumors. Some drugs worked better than others.

Methodology

The study used two clones of a human fibrosarcoma cell line to test the effects of various compounds on cell growth and morphology.

Limitations

The study primarily focused on specific cell lines and may not represent all types of tumors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication